Economic losses due to oncologic diseases related to modifiable risk factors

View or download the full article: 
PDF icon health-risk-analysis-2020-1-15.pdf
UDC: 
614.2
DOI: 
10.21668/health.risk/2020.1.15.eng
Authors: 

A.V. Kontsevaya, Yu.A. Balanova, A.O. Myrzamatova, M.B. Khudyakov, D.K. Mukaneeva, O.M. Drapkina

Organization: 

National Medical Research Center for Preventive Medicine, bld. 10, Petroverigskiy lane, Moscow, 101990, Russian Federation

Abstract: 

As per data provided by the WHO, about one third of death cases due to cancer are caused by risk factors that can be modified. Also, according to data provided by several authors, 4 modifiable risk factors cause 70% of malignant neoplasm cases that could have been prevented. Malignant neoplasms occupy the 2nd rank place in mortality structure in the Russian Federation. A significant share of analyzed malignant neoplasms can potentially be prevented provided that risk factors are corrected; therefore, investments into prevention should be a core in any activity aimed at public health improvement.
Our goal was to evaluate economic losses that occurred due to most common oncologic diseases related to behavioral risk factors among population in Russia in 2016 (including costs borne by the public healthcare and losses in the economy).
Our analysis comprised direct expenses borne by the public healthcare or, in other words, money spent on oncologic diseases treatment, direct funds allocated to pay disability allowances and temporary disability payments as well as indirect losses in the economy associated with untimely deaths and disability among employable population.
Aggregated economic losses that occurred due to 10 most common malignant neoplasms included into our analysis amounted to 241.3 billion rubles or 0.3% of the country GDP in 2016. Direct expenses accounted for 71.7% of the total losses while GDP losses caused by untimely deaths and disability amounted to 28.3%. The highest direct expenses borne by the public healthcare were due to colorectal cancer (52 billion rubles) and cancer in the trachea, bronchial tubes, and lungs (50 billion rubles).
Our data indicate it is necessary to invest into oncologic diseases prevention and treatment. These investments can produce a significant economic effect in long-term period thus making for economic growth.

Keywords: 
economic losses, risk factors, oncologic diseases, public healthcare, expenses, economic losses, direct costs, indirect costs.
Kontsevaya A.V., Balanova Yu.A., Myrzamatova A.O., Khudyakov M.B., Mukaneeva D.K., Drapkina O.M. Economic losses due to oncologic diseases related to modifiable risk factors. Health Risk Analysis, 2020, no. 1, pp. 133–141. DOI: 10.21668/health.risk/2020.1.15.eng
References: 
  1. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost' i smertnost') [Malignant neoplasms in Russia in 2016 (morbidity and mortality)]. In: A.D. Kaprin, V.V. Starinskii, G.V. Petrova eds. Moscow, Moskovskii nauchno-issledovatel'skii onkologicheskii institute imeni P.A. Gertsena – filial «Natsional'nogo meditsinskogo issledovatel'skogo tsentra radiologii» Minzdrava Rossii Publ., 2018, 250 p. (in Russian).
  2. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2017 godu [The existing situation with providing oncologic aid to population in Russia in 2017]. In: A.D. Kaprin, V.V. Starinskii, G.V. Petrova eds. Moscow, Moskovskii nauchno-issledovatel'skii onkologicheskii institute imeni P.A. Gertsena – filial «Natsional'nogo meditsinskogo issledovatel'skogo tsentra radiologii» Minzdrava Rossii Publ., 2018, 236 p. (in Russian).
  3. Plummer M., De Martel C., Vignat J., Ferlay J., Bray F., Franceschi S. Global burden of cancers attributable to infec-tions in 2012: a synthetic analysis. Lancet Glob. Heal, 2016, vol. 9, no. 4, pp. 609–616. DOI: 10.1016/S2214-109X(16)30143-7
  4. Parkin D.M., Boyd L., Walker L.C. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br. J. Cancer, 2011, vol. 105, no. 2, pp. 77–81. DOI: 10.1038/bjc.2011.489
  5. Bloom D.E., Cafiero E.T., Jané-Llopis E., Abrahams-Gessel S., Bloom L.R., Fathima S., Feigl A.B., Gaziano T. [et al.]. The Global Economic Burden of Non-communicable Diseases. Geneva, 2011, pp. 15–31.
  6. Luengo-Fernandez R., Leal J., Gray A., Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol, 2013, vol. 14, no. 12, pp. 1165–1174. DOI: 10.1016/S1470-2045(13)70442-X
  7. Andrade P., Sacristan J.A., Dilla T. The Economic Burden of Cancer in Spain: A Literature Review. Health Econ. Outcome. Res., 2017, vol. 3, no. 1, pp. 1–8. DOI: 10.4172/2471-268X.1000125
  8. Yabroff K.R., Lund J., Kepka D., Mariotto A. Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. Cancer Epidemiol. Biomarkers. Prev., 2011, vol. 20, no. 10, pp. 2006–2014. DOI: 10.1158/1055-9965.EPI-11-0650
  9. Ignat'eva V.I., Derkach E.V., Omel'yanovskii V.V., Avksent'eva M.V. Methodological problems of evaluating the economic burden of malignant tumors in Russia. Meditsinskie tekhnologii. Otsenka i vybor, 2017, vol. 28, no. 2, pp. 79–86 (in Russian).
  10. Khvastunov R.A., Ivanov A.I. Rasprostranennaya adenokartsinoma zheludka: prognoz, klinicheskoe techenie, lechenie, farmakoekonomicheskie aspekty [Wide-spread stomach adenocarcinoma: forecast, clinical course, treatment, and pharmaceutical and economic aspects]. Lekarstvennyi vestnik, 2014, vol. 4, no. 56, pp. 10–14 (in Russian).
  11. Pavlysh A.V., Kolbin A.S., Kasimova A.R. Harmacoeconomic analysis of the use of oxaliplatin chemotherapy for colorectal cancer. Real (actual) clinical practice data. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemi-ologiya, 2014, vol. 7, no. 3, pp. 26–29 (in Russian).
  12. Bazin I.S., Omel'yanovskii V.V., Krysanov I.S., Ivakhnenko O.I. Social and economic burden of hepatocellular carcinoma in the Russian Federation. Kreativnaya khirurgiya i onkologiya, 2011, no. 4, pp. 22–25 (in Russian).
  13. Krysanov I.S., Sveshnikova N.D., Tsfasman F.M. Cost-effectiveness of drugs for smoking cessation in Russia. Med-itsinskie tekhnologii. Otsenka i vybor, 2011, no. 2, pp. 16–22 (in Russian).
  14. Ignat'eva V.I., Gretsova O.P., Stenina M.B., Omel'yanovskii V.V., Derkach E.V., Dombrovskii V.S. Social and Economic Burden of Breast Cancer in the Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor, 2016, vol. 4, no. 26, pp. 32–49 (in Russian).
  15. Shakhanina I.L., Namazova-Baranova L.S., Krasnopol'skii V.I., Kozachenko V.P., Prilepskaya V.N., Shchurov D.G., Tolkushin A.G. Economic analysis of a vaccine against human papillomavirus in Moscow. Epidemiologiya i vaktsinoprofilaktika, 2010, vol. 54, no. 5, pp. 69–74 (in Russian).
  16. Ignat'eva V.I., Derkach E.V., Omel'yanovskii V.V., Avksent'eva M.V. Ekonomicheskoe bremya zlokachestvennykh novoobrazovanii yaichnikov v Rossiiskoi Federatsii [Economic burden related to malignant neoplasms in the ovaries in the Russian Federation]. Onkoginekologiya, 2009, pp. 29–34 (in Russian).
  17. Derkach E.V., Ignat'eva V.I., Shirokorad V.I., Omel'yanovskii V.V., Avksent'eva M.V. Social and economic burden of prostate cancer in Russia. Meditsinskie tekhnologii. Otsenka i vybor, 2012, vol. 8, no. 2, pp. 34–45 (in Russian).
  18. Ignat'eva V.I., Derkach E.V., Omel'yanovskii V.V., Avksent'eva M.V. The Social and Economic Burden of Cancer in the Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor, 2013, no. 4, pp. 73–80 (in Russian).
  19. Weisman M., Cannon G., Butrum R., Martin G., Higginbotham S., Heggie S., Jones C., Fletcher M. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: American Institute for Cancer Research (AICR), 2007, 167 p.
  20. Xi B., Veeranki S.P., Zhao M., Ma C., Yan Y., Mi J. Relationship of Alcohol Consumption to All-Cause, Cardiovascular, and Cancer-Related Mortality in U.S. Adults. J. Am. Coll. Cardiol, 2017, vol. 70, no. 8, pp. 913–922. DOI: 10.1016/j.jacc.2017.06.054
  21. Kyu H.H., Bachman V.F., Alexander L.T., Mumford J.E., Afshin A., Estep K., Veerman J.L., Delwiche K. [et al.]. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study. BMJ, 2013, vol. 9, no. 354, pp. i3857. DOI: 10.1136/bmj.i3857
  22. Duan P., Hu C., Quan C., Yi X., Zhou W., Yuan M., Yu T., Kourouma A., Yang K. Body mass index and risk of lung cancer: Systematic review and dose-response meta-analysis. Sci. Rep., 2015, vol. 5, no. 1, pp. 16938. DOI: 10.1038/srep16938
  23. Norat T., Aune D., Vieira A.R., Chan D., Rosenblatt D.N. Systematic Literature Review Continuous Update Project Report: The Associations between Food, Nutrition and Physical Activity and the Risk of Pancreatic Cancer. Toulouse, 2010, pp. 131–156.
  24. Luo A.J., Wang F.Z., Luo D., Hu D.H., Mao P., Xie W.Z., He X.F., Kan W., Wang Y. Consumption of vegetables may reduce the risk of liver cancer: Results from a meta-analysis of case-control and cohort studies. Clin. Res. Hepatol. Gastro-enterol, 2015, vol. 39, no. 1, pp. 45–51. DOI: 10.1016/j.clinre.2014.08.003
  25. Chislennost' lits, vpervye priznannykh invalidami. Dannye Mintruda Rossii, raschet Rosstata s 1995–2017 gg. [A number of people who were established to be disabled for the first time. Data provided by the RF Labor Ministry and calculated by Rosstat over 1995 – 2017.]. Federal'naya sluzhba gosudarstvennoi statistiki. Available at: http://www.gks.ru/
    wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/healthcare/# (29.11.2018) (in Russian).
  26. Srednii razmer naznachennykh pensii invalidov, sostoyashchikh na uchete v sisteme pensionnogo fonda Rossiiskoi Federatsii (po sostoyaniyu na 1 yanvarya). Federal'naya sluzhba gosudarstvennoi statistiki. Available at: http://www.
    gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/disabi (11.12.2018) (in Russian).
  27. Kontsevaya A.V., Drapkina O.M., Balanova Yu.A., Imaeva A.E., Suvorova E.I., Khudyakov M.B. Economic Burden of Cardiovascular Diseases in the Russian Federation in 2016. Ratsional'naya farmakoterapiya v kardiologii, 2018, vol. 14, no. 2, pp. 156–166 (in Russian).
  28. De Oliveira С., Weir S., Rangrej J. The economic burden of cancer care in Canada: a population-based cost study. CMAJ, 2018, vol. 6, no. 1, pp. E1–E10. DOI: 10.9778/cmajo.20170144
  29. Krueger H., Andres E.N., Koot J.M., Reilly B.D. The economic burden of cancers attributable to tobacco smoking, excess weight, alcohol use, and physical inactivity in Canada. Curr. Oncol, 2016, vol. 23, no. 4, pp. 241–249. DOI: 10.3747/co.23.2952
Received: 
12.11.2020
Accepted: 
09.02.2020
Published: 
30.03.2020

You are here

Home